American Society of Addiction Medicine

This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine

  • Lead: Epigenome-wide association study on methamphetamine dependence

Lead: Epigenome-wide association study on methamphetamine dependence

Tuesday 2nd April 2024

Dive into groundbreaking research on methamphetamine dependence, cannabis use trends, and innovative treatments for opioid use disorder.
6 minutes
Informative
Engaging
Educational
Supportive
Eye-opening

About this podcast

This Week in Addiction Medicine from ASAM
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Epigenetic Insights into Methamphetamine Dependence and More

Episode Overview

  • Methamphetamine dependence is linked to specific epigenetic changes.
  • Cannabis use has increased in Canada post-legalisation.
  • Offering buprenorphine during incarceration may improve post-release outcomes.
  • Primary care can effectively manage opioid use disorder with swift medication initiation.
  • Patients face various hurdles when discontinuing buprenorphine treatment.
Hypomethylation of the CNOT1 and PUM1 genes could be tied to symptoms like psychosis.
Ever wondered how methamphetamine dependence affects the brain at a genetic level? This episode of 'This Week in Addiction Medicine from ASAM' dives into a groundbreaking study that explores the epigenetic changes associated with methamphetamine use. Researchers found 13 regions with differential methylation, shedding light on the biological changes linked to addiction. Particularly intriguing are the hypomethylation of the CNOT1 and PUM1 genes, which could be tied to symptoms like psychosis, commonly seen in mood disorders and schizophrenia.
The episode also covers a variety of other studies that touch on different aspects of addiction and its treatment. From the rise in cannabis use post-legalisation in Canada to the benefits of offering buprenorphine during incarceration, there's a wealth of information here. The discussion on how primary care can effectively address opioid use disorder offers practical insights for healthcare providers. You'll also hear about patients' perspectives on discontinuing buprenorphine treatment, highlighting logistical hurdles and personal challenges.
Plus, there's an intriguing piece on the potential of psychedelics as a treatment for addiction, urging modern medicine to learn from indigenous practices. This episode is packed with research findings that not only inform but also provoke thought about the future of addiction treatment. Whether you're in the medical field or have a personal interest in addiction recovery, this episode offers valuable insights and practical advice.
Don't miss out on these compelling discussions that could change how we understand and treat addiction.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.